BriaCell reports positive clinical data for breast cancer targeted immunotherapy
BriaCell reports positive clinical data for breast cancer targeted immunotherapy
Bill Williams, President and CEO of BriaCell Therapeutics (CVE: BCT) tells Proactive Investors they believe they will literally “change the face of cancer immunotherapy.”
Williams says BriaCell’s approach is unique in that they have a personalized “off the shelf” approach to immunotherapy for cancer, targeting advanced breast cancer.
Immunotherapy News from China
- UPDATE 2-U.S. FDA approves Merck immunotherapy/chemo combo …
- …Announces Off-the-Shelf CAR T-cell Cancer Immunotherapy to…
- UPDATE 2-U.S. FDA approves Merck immunotherapy/chemo combo …
- …in Combination With Anti-PD-L1 Cancer Immunotherapy and …
- …Dosed in First-in-Human Clinical Study of Immunotherapy …
- JITC tumor and cancer immunotherapy papers collection
- Welcome to the submission|Journal for ImmunoTherapy of Cancer
- Immunotherapy shows promise for advanced lymphoma: study
- …from the Monotherapy Arm at the Phacilitate Immunotherapy …
- Allergy Immunotherapy Market to exceed US$ 3.33 Bn by 2025 …
Leave a Reply
You must be logged in to post a comment.